Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer
Dr. Raskin is a psychiatrist and academic with 20 years of international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch, and commercialization
Mind Cure Health Inc. (CNSX: MCUR) (OTCMKTS: MCURF), a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce the appointment of Dr. Joel Raskin as Chief Medical Officer. A trusted and respected leader in the neuroscience community, Dr. Raskin possesses two decades of international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch, and commercialization.
As Chief Medical Officer with MINDCURE, Dr. Raskin will play a lead role in the company’s drug research, development, and commercialization approach. He has additional expertise around several priority indications identified by MINDCURE, including migraines, depression, and anxiety. Dr. Raskin earned his Medical degree and his FRCPC Psychiatry from the University of Toronto. Dr. Raskin had a 20-year career holding various neuroscience leadership positions at pharmaceutical company Eli Lilly & Co. He currently serves on the Alzheimer’s Drug Development Foundation Scientific Review Committee and the Weston Family Foundation Brain Institute Scientific Advisory Committee.
“I am thrilled today to be joining the team at MINDCURE as Chief Medical Officer,” said Dr. Joel Raskin. “In my 35 years of pharmaceutical and psychiatric experience, I have seen firsthand the shortcomings of existing treatments and drugs. It is an exciting opportunity ahead for MINDCURE, and this industry in general, to find more effective and safer treatments for psychiatric and neurological diseases.”
As we continue to build our world-class executive team, we are extremely pleased to welcome Dr. Raskin to MINDCURE. Dr. Raskin is a recognized leader in the area of neuropsychiatry research and treatment, and he will play a key role in advancing our mission to improve mental health in our communities through scientific psychedelic research and drug development.
Kelsey Ramsden, President and CEO of MINDCURE
About Dr. Joel Raskin
Dr. Joel Raskin was a community psychiatrist and academic with 20 years of international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch, and commercialization. He earned his medical degree and FRCPC, Psychiatry at the University of Toronto. He is currently on the Alzheimer’s Drug Development Foundation Scientific Review Committee and the Weston Family Foundation Brain Institute Scientific Advisory Committee.
Dr. Raskin is a member of the Canadian Medical Association, Ontario Medical Association, and Royal College of Physicians and Surgeons. As an active member of the academic and life sciences community, Dr. Raskin, until recently, held an adjunct staff appointment with the University of Toronto Department of Psychiatry.
To view the original press release in its entirety click here
